EZH2 and lymphoma: Finally, preclinical studies have shown that single agent EZH2 inhibitors induce significant cell killing only in EZH2 mutant-bearing lymphomas, which represent a fraction (20%) of GCB DLBCL patients [15] with high unmet clinical need.